Saturday, July 04, 2020 9:08:50 PM
Recent GNPX News
- Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 03/22/2024 08:10:00 PM
- Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 03/19/2024 05:24:00 PM
- Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 03/19/2024 12:36:00 PM
- Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers • PR Newswire (US) • 03/12/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 02:18:38 PM
- Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting • PR Newswire (US) • 03/06/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 01:45:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:34:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:32:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:28:09 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:14:47 PM
- Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators • PR Newswire (US) • 02/07/2024 01:15:00 PM
- Genprex to Present at Upcoming BIO CEO & Investor Conference • PR Newswire (US) • 02/06/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 01:15:59 PM
- Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer • PR Newswire (US) • 02/05/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 12:30:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 02:00:20 PM
- Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024 • PR Newswire (US) • 01/31/2024 01:42:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:17:02 PM
- Genprex Provides Business Update and Outlook for 2024 • PR Newswire (US) • 01/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:35:33 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/13/2023 09:50:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 09:44:44 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 04:31:18 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/03/2023 08:19:09 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM